Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Diana Rabadi Marar

Internal Medicine Council Bluffs, IA Medical Doctor

NPI 1366458945 CMS profile 197925

1701 West Broadway, Council Bluffs, IA 51501

Open in the dashboard

General payments

$25,462

1,299 records reported · program years 2019–2025

Research payments

$4,392

Paid to them · 25 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diana Rabadi Marar of Council Bluffs, IA is reported in the CMS Open Payments database as having received $25,462 across 1,299 general payments and $4,392 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,696 174
2024 General $3,258 176
2023 General $3,278 198
2022 General $2,834 178
2022 Research $3,200 11
2021 General $3,586 224
2020 General $2,998 179
2019 General $4,812 170
2019 Research $1,192 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diana Rabadi Marar
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Diana Rabadi Marar were reported at $4,696. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Diana Rabadi Marar Internal Medicine median Middle half National median
2019 $4,812 $159 $48–$570 $163
2020 $2,998 $119 $33–$402 $114
2021 $3,586 $135 $37–$521 $132
2022 $2,834 $141 $42–$496 $149
2023 $3,278 $149 $45–$519 $160
2024 $3,258 $154 $47–$537 $164
2025 $4,696 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $2,178 156 payments
  2. Amgen Inc. $2,084 118 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $1,987 45 payments
  4. AstraZeneca Pharmaceuticals LP $1,955 74 payments
  5. Novo Nordisk Inc $1,816 109 payments
  6. Novo Nordisk AS $1,766 4 payments
  7. AbbVie, Inc. $1,330 94 payments
  8. Gilead Sciences, Inc. $1,136 58 payments
  9. Astellas Pharma US Inc $1,070 36 payments
  10. Pfizer Inc. $970 63 payments
  11. Other $9,170 542 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,848 1,272 payments
  2. Travel and Lodging $1,366 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,278 1 payment
  4. Education $970 23 payments
Products named General payments · program years 2019–2025
  1. Kerendia $1,972 44 payments
  2. Lynkuet $1,293 2 payments
  3. FARXIGA $1,285 43 payments
  4. Repatha $1,260 72 payments
  5. Ozempic $1,078 73 payments
  6. MOUNJARO $983 66 payments
  7. RYBELSUS $852 57 payments
  8. ELIQUIS $707 42 payments
  9. JARDIANCE $667 49 payments
  10. XARELTO $618 48 payments
  11. Other $18,276 1,139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $3,200 11 payments
  2. Gilead Sciences, Inc. $1,192 14 payments

Prescribing to Medicare patients

Part D · data year 2024 · 144 drugs

Part D claims

7,759

Median for Internal Medicine: 777

Drug cost

$1,495,060

Median for Internal Medicine: $73,373

Branded share of claims

30.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 167 $215,616
Farxiga Dapagliflozin Propanediol Brand 197 $183,845
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 153 $127,536
Kerendia Finerenone Brand 148 $110,330
Eliquis Apixaban Brand 88 $70,795
Tresiba Flextouch U-200 Insulin Degludec Brand 42 $65,230
Xarelto Rivaroxaban Brand 84 $64,666
Xifaxan Rifaximin Brand 21 $63,663
Trulicity Dulaglutide Brand 53 $53,773
Myrbetriq Mirabegron Brand 74 $51,414

The 10 drugs with the highest cost, of 144 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$56,205

Of which drugs: $11,017

Medicare patients

107

Average age 73

Services billed

1,430

84 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Chronic kidney disease 50%
Osteoporosis 32%
Arthritis 31%
Depression 27%
Diabetes 26%
COPD 24%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 35 35 $10,073
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 41 41 $898

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 45 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZENPEP
$328 — —
MOUNJARO
$263 167 —
Kerendia
$245 148 —
Veozah
$155 12 —
XIFAXAN
$137 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 45 with Patron

Records

1,324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record